EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4)

Yoshiya Tanaka iD, Tsutomu Takeuchi, Yoshiaki Morita, Daisuke Kato iD, Yuichiro Kaneko, Wataru Terada

Modern Rheumatology · 2024

DOI: 10.1093/mr/road059 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Yoshiya Tanaka und 5 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We evaluated remission rates and their relationship with baseline characteristics in patients with rheumatoid arthritis treated with the oral Janus kinase inhibitor peficitinib.

Methods

This post hoc analysis of data from two Phase 3 studies (RAJ3 and RAJ4) of peficitinib (100 and 150 mg/day) in Asian rheumatoid arthritis patients investigated clinical disease activity index (CDAI) remission and low disease activity rates from baseline to Week 52. CDAI, Health Assessment Questionnaire-Disability Index, and van der Heijde–modified total Sharp score remission/low disease activity rates at Week 52 were evaluated among patients achieving CDAI remission at Weeks 12/28. Logistic regression analyses explored the relationship between baseline characteristics and CDAI remission/low disease activity rates.

Results

CDAI remission rates increased over time in a dose-dependent manner in both peficitinib-treated groups. Most patients achieving CDAI remission at Weeks 12/28 also achieved remission at Week 52. Following the multivariate analysis of demographic and baseline characteristics, factors associated with the achievement of CDAI remission at Week 28 included male sex, low baseline prednisone dose (RAJ3 only), and low baseline Disease Activity Score 28-C-reactive protein (RAJ4 only).

Conclusions

Peficitinib demonstrated persistent efficacy in clinical remission to Week 52. Baseline characteristics associated with CDAI remission were mostly consistent with previous studies using other disease-modifying antirheumatic drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsHumansMaleJapanTreatment OutcomeSeverity of Illness IndexRemission InductionAdamantaneNiacinamide

Stichwörter der Autor:innen

Rheumatoid arthritislow disease activitypeficitinibremissiontargeted synthetic DMARDs

Substanzen

peficitinibAntirheumatic AgentsAdamantaneNiacinamide

Autor:innen und Institutionen

  • The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Saitama Medical University, Saitama, Japan.
  • Medical Affairs Japan, Astellas Pharma Inc., Tokyo, Japan.
  • Sustainability Department, Astellas Pharma Inc., Tokyo, Japan.
  • Statistical & RWD Science Group, Data Science, Astellas Pharma Global Development Inc., Northbrook, IL, USA.

ORCID-Profile: Yoshiya Tanaka, Daisuke Kato

Zitieren

APA

Tanaka, Y., Takeuchi, T., Morita, Y., Kato, D., Kaneko, Y., & Terada, W. (2024). Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4). Modern Rheumatology. https://doi.org/10.1093/mr/road059

Vancouver

Tanaka Y, Takeuchi T, Morita Y, Kato D, Kaneko Y, Terada W. Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4). Modern Rheumatology. 2024. doi:10.1093/mr/road059

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Yoshiya and Takeuchi, Tsutomu and Morita, Yoshiaki and Kato, Daisuke and Kaneko, Yuichiro and Terada, Wataru},
  title = {Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4)},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road059}
}
Kostenlos starten →